In this article LLY Follow your favorite stocks CREATE FREE ACCOUNT Eli Lilly Foundayo GLP-1 weight loss pill. Courtesy: Eli Lilly Eli Lilly said on Thursday its newly approved obesity pill helped reduce the risk of major cardiovascular events at a similar rate as insulin glargine in adults with type 2 diabetes and obesity, meeting the main goal of a long late-stage trial. In the study of more tha...
In this article LLY Follow your favorite stocks CREATE FREE ACCOUNT Eli Lilly Foundayo GLP-1 weight loss pill. Courtesy: Eli Lilly Eli Lilly said on Thursday its newly approved obesity pill helped reduce the risk of major cardiovascular events at a similar rate as insulin glargine in adults with type 2 diabetes and obesity, meeting the main goal of a long late-stage trial. In the study of more than 2,700 adults, patients taking Foundayo had a 16% lower risk of heart attack, stroke or cardiovascular death, and a 57% lower risk of death from any cause compared with those on insulin glargine. Patients taking Foundayo also saw bigger drops in blood sugar and weight after a year, while those on insulin glargine gained weight, the company said. Lilly said it will seek U.S. approval of Foundayo for type 2 diabetes under the Commissioner's National Priority Review Voucher, and will submit an application for it by the end of the second quarter. Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.
RHJ/iStock via Getty Images Americas Gold and Silver ( USAS ) up 1.4% pre-market Thursday after saying Q1 consolidated silver production surged 76% Y/Y to a company record 787K oz, while the company sold a record 830K oz due to a positive adjustment for timing of concentrate sales. Consolidated Q1 production of lead totaled 2M lbs, copper output came in at 967K lbs, and antimony production amassed...
RHJ/iStock via Getty Images Americas Gold and Silver ( USAS ) up 1.4% pre-market Thursday after saying Q1 consolidated silver production surged 76% Y/Y to a company record 787K oz, while the company sold a record 830K oz due to a positive adjustment for timing of concentrate sales. Consolidated Q1 production of lead totaled 2M lbs, copper output came in at 967K lbs, and antimony production amassed 137K lbs. Americas Gold and Silver ( USAS ) said it is on schedule to complete Phase 2 upgrades to the No. 3 shaft at Galena, which will increase skipping speeds to ~105 short tons per hour; the upgrades will be completed during a planned two-week shutdown during the quarter. The company said the upgrade will boost ore hoisting capability in the No. 3 shaft, a significant step forward for operations at Galena as it continues to ramp up tonnage resulting from the transition to long hole stoping. More on Americas Gold and Silver Americas Gold and Silver Q4 2025 Earnings Call Transcript Americas Gold and Silver: The Market Is Looking At 2026, Not 2025 Financial information for Americas Gold and Silver
OpenAI ( OPENAI ) is trying to deepen the use of artificial intelligence in the life sciences, according to a new research paper published by the company. While noting that the 20th century was a century of discovery and saving countless lives, OpenAI's researchers noted that progress has slowed down. Drug development costs are nearly doubling every nine years; clinical trials are taking roughly 7...
OpenAI ( OPENAI ) is trying to deepen the use of artificial intelligence in the life sciences, according to a new research paper published by the company. While noting that the 20th century was a century of discovery and saving countless lives, OpenAI's researchers noted that progress has slowed down. Drug development costs are nearly doubling every nine years; clinical trials are taking roughly 7.5 years on average to complete; and diseases such as cancer, heart disease, stroke, diabetes, and more still account for roughly 74% of all deaths globally. And that is where AI comes in, according to the researchers. “AI is beginning to jumpstart that progress, with approximately 200,000 global weekly users – from the United States and Great Britain, to India and South Korea – already relying on ChatGPT for advanced life sciences work that helps researchers integrate knowledge and translate across the disciplinary gaps that act as barriers to discovery,” the researchers wrote in the paper. They continued: “These users include a seemingly terminal patient who used ChatGPT to outpace his rare cancer while processing massive amounts of personal data to identify experimental treatments; rare-disease families that have used ChatGPT to go beyond their diagnostic odyssey and surface possible treatments, communities, and experts; and AI-native startups that have built lean platforms for novel drug candidates.” The researchers pointed to Eroom's Law, which is Moore's Law in reverse. They noted that scientific research has slowed as more knowledge is gained. “The slowdown in life-science progress is not confined to pharmaceuticals. Bloom et al showed that across industries, research effort keeps rising while per-researcher productivity falls sharply,” the researchers explained. “U.S. research productivity has declined 41-fold since the 1930s. The reason is structural. As knowledge accumulates, each generation of scientists must spend more time training, only to specialize more narr...
Jeremy Edwards The Trump administration signaled this week that Federal Reserve Chair Jerome Powell should not remain in his role past May 15, when his term expires, without a confirmed successor, setting up a potential legal showdown with the central bank over who holds authority to appoint interim leadership. Now, here are the key developments to watch from The Wall Street Journal: The May 15 de...
Jeremy Edwards The Trump administration signaled this week that Federal Reserve Chair Jerome Powell should not remain in his role past May 15, when his term expires, without a confirmed successor, setting up a potential legal showdown with the central bank over who holds authority to appoint interim leadership. Now, here are the key developments to watch from The Wall Street Journal: The May 15 deadline looms: Fed Chair Jerome Powell’s term is set to expire without a confirmed successor in place, creating an unprecedented vacancy scenario at the top of the nation’s central bank during a period of significant economic uncertainty and ongoing monetary policy deliberations. Administration draws hard line: The White House has made clear its position that Powell should not continue serving as chair beyond the expiration date, marking a sharp escalation in the long-standing tension between President Trump and the Fed chief he initially appointed during his first term. Bessent names alternatives: Treasury Secretary Scott Bessent publicly floated Vice Chair Philip Jefferson and Governor Christopher Waller as potential interim leaders, signaling the administration is actively preparing contingency plans and may seek to install its preferred choice rather than allow Powell to remain. Legal ambiguity at center stage: The law does not clearly specify what happens when a Fed chair’s term expires without a confirmed successor, leaving open a critical question: Does the White House or the Federal Reserve itself hold the authority to determine interim leadership arrangements? Institutional clash brewing: The White House and the Federal Reserve hold fundamentally different interpretations of succession authority, raising the prospect of a constitutional confrontation that could test the boundaries of central bank independence and unsettle financial markets. Dear readers: We recognize that politics often intersects with the financial news of the day, so we invite you to click here to...
Curaleaf ( CURLF ) plans to commence a normal course issuer bid to repurchase up to 34,388,831 of its subordinate voting shares, representing ~5% of the subordinate voting shares issued and outstanding as of April 10, 2026. The program will run from April 20, 2026, through April 19, 2027. Source: Press Release More on Curaleaf Holdings, Inc. Curaleaf: Not Reaching For A Mixed Bag Curaleaf Benefits...
Curaleaf ( CURLF ) plans to commence a normal course issuer bid to repurchase up to 34,388,831 of its subordinate voting shares, representing ~5% of the subordinate voting shares issued and outstanding as of April 10, 2026. The program will run from April 20, 2026, through April 19, 2027. Source: Press Release More on Curaleaf Holdings, Inc. Curaleaf: Not Reaching For A Mixed Bag Curaleaf Benefits From International Expansion While The Cannabis Sector Remains Weak Curaleaf Holdings, Inc. (CURA:CA) Q4 2025 Earnings Call Transcript Curaleaf to refinance debt with $500 million senior secured notes offering Curaleaf expects Q4 revenue of $330M
martinrlee BTIG initiated coverage on Dick's Sporting Goods ( DKS ) with a Buy rating on its view that the integration of Foot Locker may be underappreciated by investors. Importantly, Drbul noted that Dick's ( DKS ) has a long history of successful merger integrations, including Golf Galaxy (2007), Sports Authority (2016), GameChanger (2016), and Moosejaw (2023). "We believe that the market is no...
martinrlee BTIG initiated coverage on Dick's Sporting Goods ( DKS ) with a Buy rating on its view that the integration of Foot Locker may be underappreciated by investors. Importantly, Drbul noted that Dick's ( DKS ) has a long history of successful merger integrations, including Golf Galaxy (2007), Sports Authority (2016), GameChanger (2016), and Moosejaw (2023). "We believe that the market is not giving Mr. Stack enough credit for his industry vision and meticulous M&A track record over the past few decades, including Galyan’s and Golf Galaxy," he noted. Despite investor concerns and skepticism around the Foot Locker acquisition, Drbul and his team believe that Dick's ( DKS ) DKS paid a reasonable price and are optimistic about the opportunity present. The acquisition is expected to meet the targeted accretion levels, if not exceed them. Notably, the Foot Locker acquisition is seen as further elevating Dick's ( DKS ) as a premier and valuable retail partner to many of the world's leading global sports brands. Drbul expects a continued laser focus on the execution of the core Dick's ( DKS ) business even as the Foot Locker integration plays out. On a broader look, Dick's ( DKS ) was said to be helping to shape what's next for the sporting goods industry as it has elevated its role as a partner, helping showcase product innovation and storytelling on a worldwide stage. BTIG assigned a price target of $300 to Dick's ( DKS ) to represent more than 30% upside potential. Shares of Dick's ( DKS ) rose 1.4% to $219.94 in premarket trading on Thursday. More on Dick's Sporting Goods DICK'S Sporting Goods, Inc. (DKS) Presents at J.P. Morgan Retail Round Up Forum 2026 Transcript DICK'S Sporting Goods: Strong Outlook Ahead, Shares Fairly Valued DICK'S Sporting Goods, Inc. (DKS) Q4 2025 Earnings Call Transcript DoorDash adds Foot Locker to retail marketplace UBS expects a World Cup and tax refund boost for Dick's Sporting Goods